Page 454 - Williams Hematology ( PDFDrive )

428 Part V: Therapeutic Principles Chapter 28: Therapeutic Apheresis: Indications, Efficacy, and Complications 429

TABLE 28–2. Indications for Apheresis in Hematology: Indication Category Assignments and Recommendation
Grades
Grade of
‡
Clinical Disorder Apheresis Procedure* Indication Category † Recommendation
Amyloidosis, systemic TPE IV 2C
Aplastic anemia or pure red cell aplasia TPE III 2C
Autoimmune hemolytic anemia (warm) TPE III 2C
Babesiosis, severe RBC exchange I 1C
Babesiosis, high-risk population II 2C
Catastrophic antiphospholipid syndrome TPE II 2C
Coagulation factor inhibitor
Alloantibody TPE IV 2C
Alloantibody IA III 2B
Autoantibody TPE III 2C
Autoantibody IA III 1C
Cold agglutinin disease TPE II 2C
Cryoglobulinemia TPE I 2A
IA II 2B
Cutaneous T-cell lymphoma; mycosis fungoides; Sézary ECP I 1B
syndrome (erythrodermic)
Erythrocytosis Erythrocytapheresis
Primary (polycythemia vera) I 1B
Secondary III 1C
Graft-versus-host disease, skin ECP
Chronic II 1B
Acute II 1C
Graft-versus-host disease, nonskin (acute/chronic) III 2C
Hemopoietic stem cell transplant, ABO incompatible
Major incompatibility, marrow TPE II 1B
Major incompatibility, apheresis TPE II 2B
Minor incompatibility, apheresis RBC exchange III 2C
Hemolytic uremic syndrome TPE
Atypical
Complement gene mutations II 2C
Factor H antibodies I 2C
MCP mutations IV 1C
Infection-associated
Shiga toxin associated IV 1C
Str. pneumonia-associated III 2C
Heparin-induced thrombocytopenia TPE
Precardiopulmonary bypass III 2C
Thrombosis III 2C
Hereditary hemochromatosis Erythrocytapheresis I 1B
Hyperleukocytosis (acute leukemia) Leukocytapheresis
Leukostasis I 1B
Prophylaxis III 2C
Hyperviscosity in monoclonal gammopathies TPE
Symptomatic I 1B
Prophylaxis for rituximab I 1C
(Continued )

Kaushansky_chapter 28_p0427-0436.indd 429 9/17/15 6:05 PM